Dudediligence.

Biohaven Ltd

BHVNNYSE · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

151.0M

on 2026-06-30, from 81.8M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

50M100M150MMar2024JunSepDecMar2025JunSepDec$7.50Mar2026Jun

Newest

No limit

S-3ASR of 2026-05-04. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗

$350.0M

J.P. Morgan Securities, agreement of 2023-10-02. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-10 is not read yet.

Cash

2.1 quarters

$267.9M on 2026-06-30 ÷ $127.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-11-12Public offering23,333,334$7.50$175.0M424B5 ↗